Roche's CT-388 dual incretin obesity asset offers a credible Phase 3 entry into the GLP-1 category by 2027. Vabysmo continues to take retina share from Eylea HD. Diagnostics division benefits from continued companion diagnostic demand as oncology personalizes. Pipeline depth is among industry-best with multiple late-stage Alzheimer's and oncology assets.
Thesis reviewed May 29, 2026
Roche Holding AG is headquartered in Switzerland, which is currently showing moderate signals.
🇨🇭Switzerland48NEUTRALView Switzerland risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| JNJ | Johnson & Johnson | 50 | +8% | ↓0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | ↓0% | AVOID |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
Investors who hold RHHBY may also have indirect exposure through these country funds.
CT-388 Phase 2 shows 18% weight loss with weekly dosing
Vabysmo extended interval Q16 data extends durability lead
Roche diagnostics wins major NHS contract for companion testing
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Josh GottheimerNJ | D | Buy | $1k–$15k | Jul 23, 24 | +38.3% |
| Josh GottheimerNJ | D | Sell | $1k–$15k | Jun 21, 24 | +63.1% |